Insiders Sold Foghorn Therapeutics At US$6.56, Meanwhile Stock Sits Near US$5.53
Insiders Sold Foghorn Therapeutics At US$6.56, Meanwhile Stock Sits Near US$5.53
Even though Foghorn Therapeutics Inc. (NASDAQ:FHTX) has fallen by 31% over the past week , insiders who sold US$72k worth of stock over the past year have had less luck. The average selling price of US$6.56 is still lower than the current share price, or in other words, insiders would have been better off holding on to their shares.
Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.
The Last 12 Months Of Insider Transactions At Foghorn Therapeutics
The Chief Strategy & Business Operations Officer, Fanny Cavalie, made the biggest insider sale in the last 12 months. That single transaction was for US$72k worth of shares at a price of US$6.56 each. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The silver lining is that this sell-down took place above the latest price (US$5.53). So it may not tell us anything about how insiders feel about the current share price. The only individual insider seller over the last year was Fanny Cavalie.
The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
NasdaqGM:FHTX Insider Trading Volume April 19th 2024
I will like Foghorn Therapeutics better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
Foghorn Therapeutics Insiders Are Selling The Stock
The last quarter saw substantial insider selling of Foghorn Therapeutics shares. Specifically, Chief Strategy & Business Operations Officer Fanny Cavalie ditched US$72k worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain.
Insider Ownership Of Foghorn Therapeutics
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. It appears that Foghorn Therapeutics insiders own 11% of the company, worth about US$25m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
What Might The Insider Transactions At Foghorn Therapeutics Tell Us?
An insider sold Foghorn Therapeutics shares recently, but they didn't buy any. And there weren't any purchases to give us comfort, over the last year. Insider ownership isn't particularly high, so this analysis makes us cautious about the company. We're in no rush to buy! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Foghorn Therapeutics. Case in point: We've spotted 4 warning signs for Foghorn Therapeutics you should be aware of, and 2 of them are a bit concerning.
Of course Foghorn Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
儘管Foghorn Therapeutics Inc.(納斯達克股票代碼:FHTX)在過去一週裏下跌了31%,但在過去一年裏出售了價值7.2萬美元股票的內部人士卻沒有那麼幸運。6.56美元的平均售價仍低於當前的股價,換句話說,內部人士最好持有他們的股票。
儘管我們認爲股東不應該只關注內部交易,但我們確實認爲密切關注內部人士的行爲是完全合乎邏輯的。
Foghorn Therapeutics 過去 12 個月的內部交易
首席戰略和業務運營官範妮·卡瓦利進行了過去12個月中最大規模的內部出售。這筆單筆交易以每股6.56美元的價格購買了價值7.2萬美元的股票。儘管內部拋售是負面的,但對我們來說,如果以較低的價格出售股票,則負面影響更大。一線希望是,這次拋售發生在最新價格(5.53美元)上方。因此,它可能無法告訴我們內部人士對當前股價的看法。去年唯一的個人內部賣家是範妮·卡瓦利。
下圖顯示了去年的內部交易(公司和個人)。如果你想確切地知道誰賣了、賣了多少以及何時出售,只需點擊下圖!
納斯達克通用汽車公司:FHTX 內部交易量 2024 年 4 月 19 日
如果我看到一些重大的內部收購,我會更喜歡 Foghorn Therapeutics。在我們等待的同時,請查看這份免費清單,列出了最近有大量內部收購的成長型公司。
Foghorn Therapeutics 內部人士正在出售該股票
上個季度,Foghorn Therapeutics的股票遭到大量內部拋售。具體而言,首席戰略和業務運營官範妮·卡瓦利在那段時間拋售了價值7.2萬美元的股票,我們沒有記錄任何購買記錄。有鑑於此,很難說所有內部人士都認爲股票很划算。
Foghorn Therapeutics的內部所有權
測試公司領導者與其他股東之間一致性的另一種方法是查看他們擁有多少股份。我認爲,如果內部人士擁有該公司的大量股份,這是一個好兆頭。看來Foghorn Therapeutics內部人士擁有該公司11%的股份,價值約2500萬美元。這種內部所有權水平不錯,但還沒有特別突出。這無疑表明了一定程度的一致性。
Foghorn Therapeutics的內部交易能告訴我們什麼?
一位內部人士最近出售了Foghorn Therapeutics的股票,但他們沒有購買任何股票。在過去的一年裏,沒有任何能讓我們感到安慰的購買。內部所有權並不是特別高,因此這種分析使我們對公司持謹慎態度。我們並不急於購買!除了了解正在進行的內部交易外,確定Foghorn Therapeutics面臨的風險也是有益的。一個很好的例子:我們發現了你應該注意的Foghorn Therapeutics的4個警告信號,其中兩個有點令人擔憂。
當然,Foghorn Therapeutics可能不是最好的買入股票。因此,您可能希望看到這個免費的高質量公司集合。
就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧